论文部分内容阅读
作者比较了冠状动脉血栓溶解法/再灌注疗法的增长费用及得益之间的关系。比较了静脉内和冠状动脉内给予链激霉素,静脉内纤维血浆酶原活化剂,主要血管形成术三种方法。下述四种变量,对每个生存者在费用上的差别为2-1.5倍。1.受损心肌量,2.冠状动脉闭塞至治疗的这段时间,3.从治疗到再灌注所需的时间,4.再闭塞的处理方法。静脉内给予血栓溶解药物的治疗方法,比冠状动脉内给予血栓溶解药物的治疗方法及主要血管成形术均要便宜。大面积或中等面积心肌梗死的患者,恰当的静脉给药和处理再闭塞,对每个生存者需7千至10万美
The authors compared the costs and benefits of coronary thrombolysis / reperfusion therapies. Three methods of administering streptomycin, intravenous fibrinogen activator, and major angioplasty were given intravenously and intracoronary. The following four variables, the cost of each survivor in the difference of 2-1.5 times. 1. The amount of impaired myocardium, 2. The time from the occlusion of the coronary artery to treatment, 3. The time from treatment to reperfusion, 4. Re-occlusion management. The treatment of intravenous thrombolytic drugs is cheaper than the treatment of coronary thrombolytic drugs and major angioplasty. In patients with large or medium-area MI, proper intravenous administration and treatment of reocclusion require between 7 and 10 million U.S. dollars per survivor